Oligonucleotide Modulation of miR-140-3p for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis and rheumatoid arthritis lack effective anti-inflammatory solutions, particularly in addressing the inflammatory cytokines IL1β and TNFα, which drive disease progression, and the complexity of microRNA regulation in these conditions is not fully exploited.
Innovation Solution
The use of oligonucleotides, specifically modified RNA molecules that are at least 80% identical to certain sequences, including the seed sequence CCACAGG, to induce the production of miR-140-3p and its isomiRs, which downregulate interferon gamma and beta cascades, HLA class II and I genes, providing anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for osteoarthritis and rheumatoid arthritis are used, then disease progression is managed, but effective anti-inflammatory solutions are lacking and inflammatory cytokines IL1β and TNFα continue to drive disease progression
Solution Approach 1:
The patent uses oligonucleotides as intermediary molecules that bind to and modulate microRNA activity, specifically targeting the miR-140-3p pathway. These oligonucleotides act as mediators between the therapeutic agent and the inflammatory cytokine pathways, interfering with the normal function of miR-140-3p to restore anti-inflammatory gene expression and reduce IL1β and TNFα driven inflammation.
Solution Approach 2:
The patent employs synthetic oligonucleotide copies of microRNA sequences, specifically designing molecules that mimic or interfere with endogenous miR-140-3p. By creating these molecular copies, the therapy can selectively modulate gene expression patterns to reduce inflammatory cytokine production without affecting other physiological processes.
2Reliability
If the complexity of microRNA regulation is fully exploited, then therapeutic effectiveness improves, but the complexity of microRNA variants and seed sequences increases treatment design difficulty
Solution Approach 1:
The patent focuses on specific local regions of the microRNA molecule, particularly the seed sequence region (nucleotides 2-8), to design therapeutic oligonucleotides. By targeting this specific local region rather than attempting to modulate the entire microRNA molecule, the therapy achieves selective and effective modulation of inflammatory pathways while simplifying the design process.
Solution Approach 2:
The patent systematically varies parameters of the oligonucleotide design, including sequence composition, length, and seed sequence matching, to optimize therapeutic effectiveness. By changing these parameters and testing their effects on inflammatory cytokine reduction, the researchers identified optimal configurations that balance efficacy with design simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These oligonucleotides effectively downregulate key inflammatory pathways and genes, offering a therapeutic approach to ameliorate symptoms of osteoarthritis and rheumatoid arthritis by reducing inflammation and immune response.
Implementation Method 1
Within the RISC the miRNA binds to its target mRNA through base-pairing between the so-called seed sequence (nucleotide 2-8) of the miRNA and the 3′ UTR of the mRNA
Implementation Method 2
They are transcribed in the nucleus as long transcripts called primary miRNA which are cleaved by the ribonuclease III endonuclease Drosha to shorter hairpin transcripts known as precursor miRNA (pre-miRNA)
Implementation Method 3
In the cytoplasm the double-stranded short hairpin pre-miRNA is further processed by another endoribonuclease, Dicer, which cuts off the loop to generate a mature miRNA duplex
Data Source
AI summary
The present invention relates to the use of oligonucleotides to treat inflammatory diseases, and in particular to treat osteoarthritis and rheumatoid arthritis. The oligonucleotides preferably comprise the seed sequence 5′-CCACAGG-3′ (SEQ ID NO: 6) situated at positions 2 to 8 of the oligonucleotide.